Hsbc Global Res downgraded shares of Haleon (NYSE:HLN - Free Report) from a strong-buy rating to a hold rating in a research report released on Wednesday,Zacks.com reports.
Other analysts also recently issued reports about the stock. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. HSBC reiterated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Finally, Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $10.95.
Check Out Our Latest Research Report on HLN
Haleon Stock Down 0.7 %
HLN stock traded down $0.08 during trading hours on Wednesday, reaching $10.38. 7,410,554 shares of the stock were exchanged, compared to its average volume of 6,538,672. The firm's 50-day moving average is $9.68 and its 200-day moving average is $9.86. Haleon has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a market cap of $46.97 billion, a price-to-earnings ratio of 30.51, a PEG ratio of 2.82 and a beta of 0.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.
Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. On average, equities research analysts expect that Haleon will post 0.43 earnings per share for the current year.
Haleon Increases Dividend
The company also recently declared a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This is a positive change from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. The ex-dividend date is Friday, April 25th. Haleon's dividend payout ratio is 58.97%.
Institutional Investors Weigh In On Haleon
A number of large investors have recently added to or reduced their stakes in the stock. Addison Advisors LLC boosted its position in shares of Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after acquiring an additional 1,106 shares in the last quarter. Synovus Financial Corp lifted its position in shares of Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company's stock worth $1,575,000 after buying an additional 1,216 shares during the last quarter. Haverford Trust Co boosted its stake in Haleon by 5.0% in the fourth quarter. Haverford Trust Co now owns 25,842 shares of the company's stock valued at $247,000 after buying an additional 1,233 shares in the last quarter. Bessemer Group Inc. boosted its stake in Haleon by 5.9% in the fourth quarter. Bessemer Group Inc. now owns 22,301 shares of the company's stock valued at $212,000 after buying an additional 1,236 shares in the last quarter. Finally, United Capital Financial Advisors LLC grew its position in Haleon by 3.5% in the fourth quarter. United Capital Financial Advisors LLC now owns 37,475 shares of the company's stock valued at $358,000 after acquiring an additional 1,266 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.
About Haleon
(
Get Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Read More
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
